Antibody-based drugs have long been a mainstay of treatment for many conditions, especially cancer and autoimmune diseases, but there may still be room for improving these therapies. An A*STAR study has found that changes to a part of the antibodies that’s often overlooked by protein engineers and drug companies can have dramatic effects on target binding and manufacturing yield.